News Search & Analytics
US Edition
Minimum 3 characters required!!
Report Based On Past 7 Days Data
10
Total Articles
5
Total Publisher Covering articles
6
Highest On 2017-12-10
0
Articles Got Popular On Social Media
gilead%20sciences found in Articles in last 7 Days

Top Articles

June 23 Gilead Sciences Inc: * European CHMP adopts positive opinion for Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for the treatment of all chronic Hepatitis C genotype...
Gilead gains after FDA approves lymphoma drug Yescarta
-CNBC - Wed Oct 18 17:00:07 EDT 2017
The Food and Drug Administration on Wednesday approved Gilead Science's Yescarta, a lymphoma therapy drug, sending the stock 4 percent higher in after-hours trade. Gilead said Yesc...
March 27 Gilead Sciences Inc * Gilead Sciences Inc- CEO John F. Milligan's 2016 total compensation was $13.9 million- SEC Filing * Executive chairman John Martin's FY 2016 total co...
(Corrects story published on May 30 to show that two, not three, of the studies had enrolled previously untreated patients, in third and fourth paragraphs from the bottom) * Gilead...
Gilead Sciences Inc and GlaxoSmithKline Plc will go head-to-head with rival versions of an improved class of HIV medicines, after clinical studies showed the U.S. company's new dru...
The first full length trailer for The Handmaid’s Tale just debuted! The Handmaid’s Tale is the story of life in the dystopia of Gilead, a totalitarian society in what was formerly ...
THE HANDMAID'S TALE -- The drama series, based on the award-winning, best-selling novel by Margaret Atwood, is the story of life in the dystopia of Gilead, a totalitarian society i...
Hulu sure knows how to release a haunting teaser. The streaming service on Wednesday released the latest promotional video for its dystopian series The Handmaid's Tale (above).&nbs...
Foster City drugmaker Gilead Sciences said Monday that it will buy Kite Pharma for about $11.9 billion to bolster its aging portfolio with an emerging cancer treatment. The acquisi...
April 7 Gilead Sciences Inc : * U.S. FDA approves new indications for Harvoni and Sovaldi in pediatric patients 12 years and older with chronic hepatitis C infection * Harvoni, Sov...
(Reuters) - Gilead Sciences Inc (GILD.O) said on Wednesday its second-quarter profit fell 12 percent as use of its flagship hepatitis C drugs continued to decline, but the results ...
Gilead to pay $11.9B for cancer-treatment developer Kite | The Seattle Times
-The Seattle Times - Mon Aug 28 20:06:23 EDT 2017
Gilead Sciences will pay $11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient’s immune cells to attack tumors. K...
Whistle-blower lawsuit against Gilead can proceed - SFGate
-SFGate - Fri Jul 07 17:33:41 EDT 2017
A federal appeals court on Friday reinstated a lawsuit against Bay Area pharmaceutical giant Gilead Sciences by two former employees who accused the company of concealing flawed te...
When I was in eighth grade, I stood on a chair to rail against what I perceived was my social studies teacher’s sexism. Looking back, I’m not surprised by my response, given that t...
Shares of Gilead Sciences, Inc. (NASDAQ:) have been disappointing for some time. GILD stock is down just 4.7% so far in 2017, but has tumbled more than 22% over the past year. Maki...
(Reuters) - Gilead Sciences Inc (GILD.O) posted better-than-expected third-quarter profits on Thursday, but shares fell after hours as use of its flagship hepatitis C drugs waned f...
However Gilead Sciences, Inc. (NASDAQ:) quarterly earnings report ends up after the market close (October 26), the stock’s valuation still looks very compelling. Ideally, inve...
Offred (Elizabeth Moss) and Ofglen (Alexis Bledel) are two of the women forced into --- servitude by the state. Their purpose is to provided children to powerful men whose wives...
Harvey Drives Energy, Insurance Companies Down
-Newser - Mon Aug 28 14:20:16 EDT 2017
(Newser) – Stocks are finishing little changed on a quiet day of trading as health care companies rise and energy and insurance companies slip, the AP reports. Biotech drug compani...
Even though there were some significant changes and additions, the first season of The Handmaid’s Tale followed the basic structure of Margaret Atwood’s classic novel, all the way ...
July 5 GALAPAGOS NV * NEW PHASE 2 STUDY WITH FILGOTINIB IN NON-INFECTIOUS UVEITIS‍​ * STUDY LED BY FILGOTINIB COLLABORATION PARTNER GILEAD SCIENCES, INC.‍​ * PRIMARY OUTCOME IS MEA...
Gilead Sciences Inc said on Tuesday a combination of its experimental HIV drug with existing therapies met the main goal in four late-stage studies. Gilead, which already has appro...
July 18 (Reuters) - Gilead Sciences Inc * U.S. Food and Drug Administration approves Gilead’s Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for re-treatment of adults with chronic h...
Oct 24 (Reuters) - Gilead Sciences Inc: * Announces Phase 2 results for GS-0976 in Nonalcoholic Steatohepatitis (NASH) * In Phase 2 study, ‍oral ACC inhibitor led to significant re...
Tonight marks the premiere of the new Hulu series The Handmaid’s Tale! The drama series, based on the best-selling novel by Margaret Atwood, is the story of life in the dystopia of...
"Better never means better for everyone." Hulu has released the full trailer for the upcoming adaptation of Margaret Atwood’s The Handmaid’s Tale, and it has a heavy unsettling vib...
“You girls will serve the leaders and their barren wives. You will bear children for them.” We’re getting the first extended look at The Handmaid’s Tale ahead of its April 26 premi...
A GROUP of charities, led by Médecins Sans Frontières, is fighting to have a drug’s patent revoked by the European Patent Office. Sofosbuvir can cure hepatitis C in just three mont...
Gilead to buy Kite Pharma for about $11 billion in cash
-CNBC - Mon Aug 28 05:00:08 EDT 2017
Gilead Sciences on has agreed to buy immunotherapy developer Kite Pharma in an all-cash deal valued at $11.9 billion, the companies said on Monday. Gilead will pay $180 per share, ...
Gilead to pay $11.9 billion for cancer treatment developer Kite  - LA Times
-Los Angeles Times - Mon Aug 28 05:46:49 EDT 2017
Gilead Sciences will pay $11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient's immune cells to attack tumors. K...
Advertisement
Publishers
Number of articles

2

5

1

1

1